focus -WSS

focus

author：leisure time 2025-09-30 16:23:51 - browse：717

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Senator probes 340B programs at Cleveland Clinic, Bon Secours

hotspot

WSS

Grail faces three suits alleging harassment, retaliation

Paxlovid should be available without a positive Covid test

Would Medicare drug price negotiations stall in a shutdown?

Federal judge rules Oregon’s tough new gun law is constitutional

Paxlovid should be available without a positive Covid test

Covid vaccines: Private market messier than government rollout

hotspot

focus

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Can CDC director Mandy Cohen drive consensus in Washington?

Guidelines to prevent youth baseball injuries need more muscle

Why do women spend more than men on medical expenses?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Blood tests recalled over risk of missed heart attack diagnosis

Moonlake's readout produced a cash windfall. Risks remain

Congress: Eradicate hepatitis C and reduce the deficit

In Memoriam: Notable people who died in 2023

Listen: Who gets the credit for GLP

focus

Biogen shutters digital health group, ends Apple study, in cost cutting move

Intercept Pharmaceuticals sells itself for less than $1 billion

Federal judge rules Oregon’s tough new gun law is constitutional

Celiac disease study examines precisely how gluten triggers injury

Who gets to use the title 'doctor'?

Menendez indictment could see pharma lose a key ally

Wikipedia

hotspot

focus

focus